Clinical trial · Interventional
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00219271CI-TRIAL-00027901completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Zoledronic acid | Drug | Zoledronic Acid | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Zoledronic acid
- description
- 4 mg IV infused over 15 minutes every 3 months
- interventionNames
- Drug: Zoledronic acid
Primary outcomes (1)
- measure
- To assess the activity of one year treatment with zoledronic acid
- timeFrame
- 12 mos
Secondary outcomes (4)
- measure
- Three-year disease free survival
- timeFrame
- 3 years
- measure
- Change in bone mineral density at 12, 24 and 36 months versus baseline
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria * Prostate cancer * Radical prostatectomy or external beam irradiation therapy within 6 months before study entry. * No bone metastases according to bone scan Exclusion Criteria * Metastatic prostate cancer * Hormone ablation therapy for more than 3 months before/after radical prostatectomy and external beam irradiation therapy * Treatment with bisphosphonates or other drugs known to affect the skeleton within the past year. Other protocol-defined inclusion / exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.